Esprinet raises 2026 EBITDA Adj guidance after 8% H1 sales growth
Esprinet reported strong H1 2026 results with 8% sales growth and a 27% higher EBITDA Adj. It raised full-year guidance, citing margin improvement and working capital efficiency.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.